For years, pathologists have been using CD34 immunohistochemistry (IHC) to study bone marrow (BM) biopsies and clot sections. The QBEND10 primary antibody clone is widely favored, but other aspects of the testing process vary greatly across different labs and in published research. To address this inconsistency, the International Council for Standardization in Hematology (ICSH) has created guidelines to standardize how CD34 IHC is performed and reported.

The ICSH reviewed existing evidence and found that while the QBEND10 antibody is the gold standard, the methods and interpretations of IHC results vary vastly. This can lead to confusion and inconsistencies in diagnosing bone marrow diseases. To solve this, the ICSH has outlined guidelines that aim to make the process more uniform.

One of the key issues is the interpretation of the IHC results. Different labs have different criteria for what constitutes a positive or negative result. The ICSH guidelines aim to create a common language for these interpretations. This will help pathologists and doctors make more accurate diagnoses.

Standardizing the IHC process also has implications for patient care. Consistency in testing means that patients are more likely to receive the correct treatment for their bone marrow conditions. It ensures that no matter where a patient goes for testing, they will receive the same high standard of care.

These guidelines are a step forward in making sure that bone marrow diagnostics are accurate and reliable. They emphasize the importance of consistent methods and clear communication in medical testing.

The Harmonized Path of CD34 IHC in Bone Marrow Diagnostics

Actions